DOP2002000336A - Inhibidores de benzotiadiazina de metaloproteinasas de la matriz - Google Patents
Inhibidores de benzotiadiazina de metaloproteinasas de la matrizInfo
- Publication number
- DOP2002000336A DOP2002000336A DO2002000336A DO2002000336A DOP2002000336A DO P2002000336 A DOP2002000336 A DO P2002000336A DO 2002000336 A DO2002000336 A DO 2002000336A DO 2002000336 A DO2002000336 A DO 2002000336A DO P2002000336 A DOP2002000336 A DO P2002000336A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- inhibitors
- benzotiadiazine
- metaloproteinases
- matrix
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Alloys Or Alloy Compounds (AREA)
Abstract
Inhibidores selectivos de MMP-13 son benzotiadiazinas de la fórmula o una sal farmacéuticamente aceptable del mismo, en donde R2 es hidrógeno o alquilo; R1 y R3 incluyen hidrógeno, alquilo y arilo, con la condición de que P.3 no sea CH2mbifenilo ni CH2mbifenilo sustituido; X es O o NH, n es 0, 1 ó 2. Los compuestos de fórmula I, o una sal farmacéuticamente aceptable de los mismos, son útiles para tratar enfermedades mediadas por una enzima MMP-13, incluidas enfermedades seleccionadas de osteoartritis, artritis reumatoide, cáncer, inflamación y fallo cardíaco.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26878201P | 2001-02-14 | 2001-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2002000336A true DOP2002000336A (es) | 2003-01-31 |
Family
ID=23024450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2002000336A DOP2002000336A (es) | 2001-02-14 | 2002-02-01 | Inhibidores de benzotiadiazina de metaloproteinasas de la matriz |
Country Status (17)
Country | Link |
---|---|
US (1) | US6656932B2 (es) |
EP (1) | EP1368327B1 (es) |
JP (1) | JP2004518726A (es) |
AT (1) | ATE280164T1 (es) |
BR (1) | BR0207865A (es) |
CA (1) | CA2433075A1 (es) |
DE (1) | DE60201665T2 (es) |
DO (1) | DOP2002000336A (es) |
ES (1) | ES2231708T3 (es) |
GT (1) | GT200200016A (es) |
HN (1) | HN2002000227A (es) |
MX (1) | MXPA03005870A (es) |
PA (1) | PA8538501A1 (es) |
PE (1) | PE20020953A1 (es) |
TN (1) | TNSN02013A1 (es) |
UY (1) | UY27155A1 (es) |
WO (1) | WO2002064578A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
WO2004007024A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
AU2003247024A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
JP2006502114A (ja) * | 2002-07-17 | 2006-01-19 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリクスメタロプロテイナーゼ−13のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ |
CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
CA2494048A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
WO2004014354A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
MXPA05001603A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados monociclicos como inhibidores de metaloproteinasa de matriz. |
AU2003249477A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
ES2283851T3 (es) | 2002-08-13 | 2007-11-01 | Warner-Lambert Company Llc | Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
WO2004014388A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
AU2003253186A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
JP2005539020A (ja) * | 2002-08-13 | 2005-12-22 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体 |
JP2006500350A (ja) * | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのイソキノリン誘導体 |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
EP1680125A1 (en) * | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
US7570259B2 (en) | 2004-06-01 | 2009-08-04 | Intel Corporation | System to manage display power consumption |
EP1828152B1 (en) | 2004-12-08 | 2008-08-20 | Bristol-Myers Squibb Company | Heterocyclic compounds as inhibitors of factor viia |
SI1860098T1 (sl) | 2005-03-16 | 2013-03-29 | Toyama Chemical Co., Ltd. | Nov derivat antranilne kisline ali sol le-tega |
EP4124616A1 (en) | 2009-06-25 | 2023-02-01 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
RS55434B1 (sr) | 2011-03-18 | 2017-04-28 | Alkermes Pharma Ireland Ltd | Injektabilne farmaceutske kompozicije koje sadrže antipsihotik koji je nerastvorljiv u vodi, sorbitan laurat i polisorbat 20 |
CA2867123C (en) | 2012-03-19 | 2021-02-16 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters |
JP6471089B2 (ja) | 2012-03-19 | 2019-02-13 | アルカームス ファーマ アイルランド リミテッド | 脂肪酸エステルを含む医薬組成物 |
JP6333802B2 (ja) | 2012-03-19 | 2018-05-30 | アルカームス ファーマ アイルランド リミテッド | ベンジルアルコールを含む医薬組成物 |
EP2897592B1 (en) | 2012-09-19 | 2020-02-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
MX2016012041A (es) | 2014-03-20 | 2017-01-19 | Alkermes Pharma Ireland Ltd | Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion. |
EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
CN113773277B (zh) * | 2021-09-18 | 2023-12-05 | 兰州大学 | 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242443B1 (en) * | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
IL128545A0 (en) * | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
EP0977738B1 (en) * | 1997-04-28 | 2005-11-16 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer |
JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用 |
EP1209319A4 (en) | 1999-07-30 | 2004-05-12 | Yosikane Ikitake | ROTARY INTERNAL COMBUSTION ENGINE EQUIPPED WITH RECIPROCATING PALLETS |
PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
KR20040004412A (ko) | 2000-10-26 | 2004-01-13 | 화이자 프로덕츠 인크. | 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
EE200300195A (et) | 2000-10-26 | 2003-10-15 | Pfizer Products Inc. | Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid |
PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
-
2002
- 2002-01-11 ES ES02740094T patent/ES2231708T3/es not_active Expired - Lifetime
- 2002-01-11 AT AT02740094T patent/ATE280164T1/de not_active IP Right Cessation
- 2002-01-11 CA CA002433075A patent/CA2433075A1/en not_active Abandoned
- 2002-01-11 BR BR0207865-1A patent/BR0207865A/pt not_active IP Right Cessation
- 2002-01-11 EP EP02740094A patent/EP1368327B1/en not_active Expired - Lifetime
- 2002-01-11 WO PCT/IB2002/000083 patent/WO2002064578A1/en active IP Right Grant
- 2002-01-11 MX MXPA03005870A patent/MXPA03005870A/es unknown
- 2002-01-11 JP JP2002564511A patent/JP2004518726A/ja not_active Abandoned
- 2002-01-11 DE DE60201665T patent/DE60201665T2/de not_active Expired - Fee Related
- 2002-02-01 DO DO2002000336A patent/DOP2002000336A/es unknown
- 2002-02-05 PA PA20028538501A patent/PA8538501A1/es unknown
- 2002-02-07 GT GT200200016A patent/GT200200016A/es unknown
- 2002-02-08 UY UY27155A patent/UY27155A1/es not_active Application Discontinuation
- 2002-02-11 HN HN2002000227A patent/HN2002000227A/es unknown
- 2002-02-12 PE PE2002000109A patent/PE20020953A1/es not_active Application Discontinuation
- 2002-02-13 TN TNTNSN02013A patent/TNSN02013A1/fr unknown
- 2002-02-13 US US10/074,646 patent/US6656932B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HN2002000227A (es) | 2002-10-23 |
ATE280164T1 (de) | 2004-11-15 |
US6656932B2 (en) | 2003-12-02 |
PE20020953A1 (es) | 2002-10-25 |
BR0207865A (pt) | 2004-03-23 |
EP1368327A1 (en) | 2003-12-10 |
TNSN02013A1 (fr) | 2005-12-23 |
DE60201665T2 (de) | 2006-02-02 |
UY27155A1 (es) | 2002-09-30 |
ES2231708T3 (es) | 2005-05-16 |
JP2004518726A (ja) | 2004-06-24 |
DE60201665D1 (de) | 2004-11-25 |
MXPA03005870A (es) | 2005-02-14 |
GT200200016A (es) | 2002-10-01 |
EP1368327B1 (en) | 2004-10-20 |
WO2002064578A1 (en) | 2002-08-22 |
CA2433075A1 (en) | 2002-08-22 |
PA8538501A1 (es) | 2002-09-17 |
US20020156069A1 (en) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2002000336A (es) | Inhibidores de benzotiadiazina de metaloproteinasas de la matriz | |
EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
EA200200976A1 (ru) | Способ лечения или ингибирования полипов ободочной кишки | |
EA200100411A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
ATE349435T1 (de) | Dpiv-inhibitoren auf glutaminbasis | |
NO953305L (no) | Antranilsyrederivat | |
EA199800579A1 (ru) | Новые производные 5-амино-3-циано-4-этилсульфинил-1-фенилпиразола и их применение в качестве пестицидов | |
IS6309A (is) | Kínasólínafleiður | |
DK1485359T3 (da) | Natriumkanalblokkere | |
ES2182234T3 (es) | Inhibidores de metaloproteasa. | |
TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
NO20072605L (no) | Nytt antranilinsyrederivat eller et salt derav | |
EA199800141A1 (ru) | Гетероциклические соединения | |
DE60002714D1 (de) | Substituierte azaoxindolederivate | |
DE69718194T2 (de) | Amidinophenyl-pyrrolidine, -pyrroline und -isoxazolidine und ihre derivate | |
CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
DK1109817T3 (da) | Phosphohalogenhydriner, deres fremstilling og anvendelse | |
NZ507835A (en) | Heterocyclic derivatives which inhibit factor XA | |
EA200000996A1 (ru) | Конденсированные с арилом азаполициклические соединения | |
ES2169242T3 (es) | 2-amino-benzoxazinonas para el tratamiento de infecciones virales. | |
DE602004031115D1 (de) | Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga | |
EA200100040A1 (ru) | Химический синтез морфолиновых производных | |
BRPI0416678A (pt) | pirazolpirimidinas | |
BR0008589A (pt) | Composto de tipirano, processo para sua preparação e seu uso | |
BR0010488A (pt) | Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas |